About SMC Laboratories
Overview
SMC Laboratories is one of our SMC Group and is a Tokyo-based non-clinical CRO that provides pharmacological studies using inflammation and fibrosis mice models and Histopathological analysis services.
They have supported more than 600 pharmaceutical companies and bio-ventures in over 30 countries with our cutting-edge research and pharmacology studies.
We are able to be a point of contact for SMC Laboratories, so if you are interested please contact us.
-
SMC Laboratories's Tokyo office
-
SMC Laboratories's Tokyo Lab.
-
Location of clients
-
Interaction between SMC Laboratories and SII
Black arrow; flow when Clients' inquiry is to SMC Laboratories blue arrow; flow when client's inquiry is in SII
SMC Laboratories Inc.
Technoport Kamata Center Bldg. 2-16-1 Minami-Kamata Ota-City Tokyo, 144-0035 Japan
TEL +81-3-6715-9101
https://www.smccro-lab.com/
CRO services
- Non-clinical pharmacology studies
-
- High-performance pharmacology utilizing the company's expertise in research
- Lineup of various disease models relating to fibrosis, inflammation, metabolic disorders and cancer
- Strategic study design proposed by experienced scientists
- Histological imaging
-
- In-house, high quality analyses; proven skills in Histology
- Elaborate and comprehensive reports by Ph.D. holders
- Professional support for data publication/IND application
Specialty Area
- Inflammation and fibrosis models
- Expertise in fibrosis in various organs (liver, kidney, lung, intestine and skin)
- Histopathological analysis
- Established new immuno-staining and scoring methods using our expertise in evaluating NASH and fibrosis.
- Through our expertise, we can easily identify balloon-like degeneration, an evaluation which has proven to be difficult by third parties, in pathological samples of NASH and fibrosis models made by clients
Animal Models
We have 18 disease animal models of inflammation and fibrosis (See table below for model list)
| Disease area | Mouse model |
|---|---|
| NASH-HCC | STAMTM model |
| Fatty liver/NAFLD | MCD model |
| Metabolic disease | nSTZ model |
| Cholestatic liver diseases | Bile duct ligation-induced liver fibrosis model |
| Liver cirrhosis | CCI4-induced liver fibrosis model |
| Acute liver failure | CCI4-induced acute liver failure model,Concanavalin A-induced acure liver failure model D-gal-LPS-induced acute liver failure model,TAA-induced acute liver failure model |
| IPF | Bleomycin-induced lung fibrosis model |
| COPD | Porcine pancreatic elastate-induced emphysema model |
| CKD | UUO-incuded renal fibrosis model,Adriamycin-induced nephropathy model Folic acid-induced chronic kidney disease model |
| Alzheimer's disease | Icv-STZ-induced Alzheimer's disease model |
| IBD | DSS-induced colitis model |
| Systemic clerosis | Bleomycin-induced skin fibrosis model |
| Cancer | Xenograft tumor model DEN-CCI4 liver cancer model |
Abbreviation
NASH:non-alcoholic steatohepatitis, HCC:hepatocelluar carcinoma, NAFLD:non-alcoholic fatty liver disease, IPF:idiopathic pulmonary fibrosis, CCOPD:chronic kidney disease, IBD:inflammatory bowel disease, STAM:stelic animal model, MCD:methionine and choline deficient, CCI4:carbon tetrachloride, STZ:streptozotocin, UUO:unilateral obstruction, DSS:dextran sodium sulfate
Among them is the STAMTM model, which is a NASH-HCC model developed by SMCL with its own technology.
Compared to other NASH-HCC model mice, the disease progresses in a relatively short period of time, and liver cancer is developed in 100% of animals at 20 weeks of age.
Thus, our model is widely used in NASH research, with more than 40 papers (seen left of the figure shown below) and 80 international conferences (listed right of the figure shown below) published using data from our STAMTM model so far.
-
Pablications
-
Presentations
Moreover, 15 companies have used data generated in pharmacology studies provided by SMC to complete CTA applications, and are currently conducting clinical trials.
For example, phase 3 and 2 trials currently being conducted by Allergan and Galectin.
